Cargando…

A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients

PURPOSE: This study aimed to investigate the clinical efficacy of tapentadol extended-release (ER) on pain control and the quality of life (QoL) of patients with moderate to severe chronic cancer pain in clinical practice in Korea. METHODS: In this prospective, open-label, multicenter trial, patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Ji Yoon, Chon, Hong Jae, Choi, Young Jin, Yeon, Sang Eun, Choi, Seok Young, Lee, Kyung Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135883/ https://www.ncbi.nlm.nih.gov/pubmed/35420330 http://dx.doi.org/10.1007/s00520-022-06992-w

Ejemplares similares

Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study
por: Sazuka, Shoichiro, et al.
Publicado: (2020)

Ready Conversion of Patients with Well-Controlled, Moderate to Severe, Chronic Malignant Tumor–related Pain on Other Opioids to Tapentadol Extended Release
por: Imanaka, Keiichiro, et al.
Publicado: (2014)

Tapentadol extended release for the management of chronic neck pain
por: Billeci, Domenico, et al.
Publicado: (2017)

Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol
por: Peacock, Amy, et al.
Publicado: (2018)

Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse
por: Cepeda, M. Soledad, et al.
Publicado: (2014)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

Effectiveness and Tolerability of Tapentadol Prolonged Release Compared With Prior Opioid Therapy for the Management of Severe, Chronic Osteoarthritis Pain
por: Steigerwald, Ilona, et al.
Publicado: (2013)

Tapentadol extended-release for treatment of chronic pain: a review
por: Vadivelu, Nalini, et al.
Publicado: (2011)

Tapentadol extended release in the management of peripheral diabetic neuropathic pain
por: Vadivelu, Nalini, et al.
Publicado: (2015)

Diversion and Illicit Sale of Extended Release Tapentadol in the United States
por: Dart, Richard C., et al.
Publicado: (2016)

Does ‘Strong Analgesic’ Equal ‘Strong Opioid’? Tapentadol and the Concept of ‘µ-Load’
por: Raffa, Robert B., et al.
Publicado: (2018)

Opioid rotation with extended-release opioids: where should we begin?
por: Nalamachu, Srinivas
Publicado: (2011)

Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study
por: Steigerwald, Ilona, et al.
Publicado: (2012)

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2018)

Trajectories of Opioid Use Following First Opioid Prescription in Opioid-Naive Youths and Young Adults
por: Wilson, J. Deanna, et al.
Publicado: (2021)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

Opioid Prescribing Habits for Common Arthroscopic Procedures in Opioid Naïve Patients
por: Thompson, Matthew M., et al.
Publicado: (2021)

Incidence of Delirium With Different Oral Opioids in Previously Opioid-Naive Patients
por: Sugiyama, Yosuke, et al.
Publicado: (2022)

Update on prescription extended-release opioids and appropriate patient selection
por: Brennan, Michael J
Publicado: (2013)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Assessment of opioid administration patterns following lower extremity fracture among opioid-naïve inpatients: retrospective multicenter cohort study
por: Ramadan, Majed, et al.
Publicado: (2022)

Differential Patterns of Adherence to Opioid Therapy in Opioid Naïve and Opioid Existing Patients With Different Age Groups
por: Zin, Che Suraya, et al.
Publicado: (2019)

Factors related to the use of opioids as early treatment in patients with knee osteoarthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2019)

Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia
por: Lam, Tina, et al.
Publicado: (2022)

Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study
por: Yen, Tsung-Yu, et al.
Publicado: (2018)

Neuroplasticity of the extended amygdala in opioid withdrawal and prolonged opioid abstinence
por: Kaplan, Gary B., et al.
Publicado: (2023)

Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?
por: Chang, Eun Jung, et al.
Publicado: (2016)

The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain
por: Kang, Jung Hun, et al.
Publicado: (2015)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy
por: Gonçalves, Leonor, et al.
Publicado: (2015)

The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy
por: Gudin, Jeffrey A
Publicado: (2012)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Opioid Prescription Consumption Patterns After Total Joint Arthroplasty in Chronic Opioid Users Versus Opioid Naive Patients
por: Kaidi, Austin C., et al.
Publicado: (2020)

Opioid Consumption Patterns and the Risk of Prolonged Opioid Use Among Opioid-Naïve Patients Following Ankle Fracture Surgery
por: Skibicki, Hope, et al.
Publicado: (2019)

Prolonged Opioid Use Among Opioid-Naive Women Undergoing Breast Reconstructive Surgery
por: Samuel, Ankhita R., et al.
Publicado: (2022)

Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial
por: Sabatowski, Rainer, et al.
Publicado: (2014)

Tapentadol Prolonged Release: A Review in Pain Management
por: Deeks, Emma D.
Publicado: (2018)

Trends in dispensing and utilisation of sustained-release tapentadol in Australia.
por: Camacho, Ximena, et al.
Publicado: (2022)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6fhj327qlu0bbbg580u3417i1m